Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Calyxt

Nasdaq:CLXT
Snowflake Description

Flawless balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
CLXT
Nasdaq
$123M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Calyxt, Inc., a consumer-centric food- and agriculture-focused company, develops healthier specialty food ingredients and food crops using gene-editing technology for agriculture in the United States. The last earnings update was 23 days ago. More info.


Add to Portfolio Compare Print
  • Calyxt has significant price volatility in the past 3 months.
CLXT Share Price and Events
7 Day Returns
14%
NasdaqGM:CLXT
6.3%
US Biotechs
12.6%
US Market
1 Year Returns
-78.7%
NasdaqGM:CLXT
1.6%
US Biotechs
-9.1%
US Market
CLXT Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Calyxt (CLXT) 14% -33.3% -41.7% -78.7% - -
US Biotechs 6.3% -7.9% -7.9% 1.6% 7.7% -8.8%
US Market 12.6% -16.7% -19.6% -9.1% 8.2% 21.5%
1 Year Return vs Industry and Market
  • CLXT underperformed the Biotechs industry which returned 1.6% over the past year.
  • CLXT underperformed the Market in United States of America which returned -9.1% over the past year.
Price Volatility
CLXT
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Calyxt undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Calyxt. This is due to cash flow or dividend data being unavailable. The share price is $3.74.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Calyxt's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Calyxt's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:CLXT PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-1.21
NasdaqGM:CLXT Share Price ** NasdaqGM (2020-03-27) in USD $3.74
United States of America Biotechs Industry PE Ratio Median Figure of 37 Publicly-Listed Biotechs Companies 15.87x
United States of America Market PE Ratio Median Figure of 2,935 Publicly-Listed Companies 13.38x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Calyxt.

NasdaqGM:CLXT PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:CLXT Share Price ÷ EPS (both in USD)

= 3.74 ÷ -1.21

-3.1x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Calyxt is loss making, we can't compare its value to the US Biotechs industry average.
  • Calyxt is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Calyxt's expected growth come at a high price?
Raw Data
NasdaqGM:CLXT PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -3.1x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts
25.1%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 34 Publicly-Listed Biotechs Companies 0.99x
United States of America Market PEG Ratio Median Figure of 2,005 Publicly-Listed Companies 1.03x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Calyxt, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Calyxt's assets?
Raw Data
NasdaqGM:CLXT PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $1.90
NasdaqGM:CLXT Share Price * NasdaqGM (2020-03-27) in USD $3.74
United States of America Biotechs Industry PB Ratio Median Figure of 428 Publicly-Listed Biotechs Companies 2.47x
United States of America Market PB Ratio Median Figure of 5,145 Publicly-Listed Companies 1.27x
NasdaqGM:CLXT PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:CLXT Share Price ÷ Book Value per Share (both in USD)

= 3.74 ÷ 1.90

1.97x

* Primary Listing of Calyxt.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Calyxt is good value based on assets compared to the US Biotechs industry average.
X
Value checks
We assess Calyxt's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Calyxt has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Calyxt expected to perform in the next 1 to 3 years based on estimates from 6 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
25.1%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Calyxt expected to grow at an attractive rate?
  • Calyxt's earnings growth is expected to exceed the low risk savings rate of 1.7%.
Growth vs Market Checks
  • Calyxt's earnings growth is expected to exceed the United States of America market average.
  • Calyxt's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:CLXT Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGM:CLXT Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts 25.1%
NasdaqGM:CLXT Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 6 Analysts 49.2%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 18.7%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 15.7%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 12.3%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:CLXT Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:CLXT Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 411 89 17 2
2023-12-31 193 3 -21 2
2022-12-31 100 -26 -45 4
2021-12-31 46 -47 -49 6
2020-12-31 16 -40 -48 6
2020-03-28
NasdaqGM:CLXT Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 7 -32 -40
2019-09-30 4 -31 -36
2019-06-30 1 -27 -33
2019-03-31 0 -23 -31
2018-12-31 0 -20 -28
2018-09-30 0 -20 -26
2018-06-30 0 -18 -32
2018-03-31 0 -18 -28
2017-12-31 1 -13 -26
2017-09-30 0 -9 -24
2017-06-30 0 -11 -13
2017-03-31 0 -9 -12

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Calyxt's earnings are expected to grow significantly at over 20% yearly.
  • Calyxt's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:CLXT Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below

All data from Calyxt Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:CLXT Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 0.37 1.92 -1.18 2.00
2023-12-31 -0.58 -0.15 -1.00 2.00
2022-12-31 -1.22 -0.88 -1.56 2.00
2021-12-31 -1.38 -1.30 -1.50 4.00
2020-12-31 -1.41 -1.32 -1.47 5.00
2020-03-28
NasdaqGM:CLXT Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -1.21
2019-09-30 -1.10
2019-06-30 -1.00
2019-03-31 -0.97
2018-12-31 -0.91
2018-09-30 -0.89
2018-06-30 -1.14
2018-03-31 -1.09
2017-12-31 -1.12
2017-09-30 -1.12
2017-06-30 -0.68
2017-03-31 -0.63

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Calyxt will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Calyxt's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Calyxt has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Calyxt performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Calyxt's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Calyxt does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Calyxt's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Calyxt's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Calyxt's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Calyxt Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:CLXT Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 7.30 -39.61 25.48 11.63
2019-09-30 3.54 -35.92 25.47 10.07
2019-06-30 0.60 -32.73 23.21 10.39
2019-03-31 0.38 -30.90 20.85 10.84
2018-12-31 0.24 -27.90 17.99 10.36
2018-09-30 0.42 -26.28 16.47 10.30
2018-06-30 0.44 -31.70 18.74 13.25
2018-03-31 0.46 -27.52 16.42 11.34
2017-12-31 0.51 -25.98 14.79 11.51
2017-09-30 0.39 -23.68 13.06 10.88
2017-06-30 0.46 -13.29 7.86 5.68
2017-03-31 0.35 -12.35 7.05 5.53
2016-12-31 0.40 -12.09 6.67 5.64
2015-12-31 1.27 -5.89 3.57 2.77

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Calyxt has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Calyxt has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Calyxt improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Calyxt's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Calyxt has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Calyxt's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Calyxt's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Calyxt is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Calyxt's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Calyxt's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Calyxt has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Calyxt Company Filings, last reported 2 months ago.

NasdaqGM:CLXT Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 62.51 0.00 58.61
2019-09-30 72.13 0.00 66.43
2019-06-30 80.19 0.00 76.43
2019-03-31 87.70 0.00 84.23
2018-12-31 93.40 0.00 93.79
2018-09-30 100.23 1.94 101.80
2018-06-30 106.24 1.34 105.62
2018-03-31 53.86 0.74 50.70
2017-12-31 57.48 0.00 56.66
2017-09-30 62.11 3.32 62.55
2017-06-30 7.58 5.81 2.52
2017-03-31 10.42 2.17 3.01
2016-12-31 13.12 1.71 5.03
2015-12-31 24.26 0.08 24.69
  • Calyxt has no debt.
  • Calyxt currently has no debt however we can't compare to 5 years ago as we have no data for that period.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Calyxt has sufficient cash runway for 1.7 years based on current free cash flow.
  • Calyxt has sufficient cash runway for 1.3 years if free cash flow continues to grow at historical rates of 33.6% each year.
X
Financial health checks
We assess Calyxt's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Calyxt has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Calyxt's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Calyxt dividends. Estimated to be 0% next year.
If you bought $2,000 of Calyxt shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Calyxt's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Calyxt's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:CLXT Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 65 Stocks 2.3%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1956 Stocks 2.9%
United States of America Minimum Threshold Dividend Yield 10th Percentile 1.1%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.9%
United States of America Top 25% Dividend Yield 75th Percentile 5.3%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:CLXT Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31 0.00 1.00
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2020-03-28

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Calyxt has not reported any payouts.
  • Unable to verify if Calyxt's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Calyxt's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Calyxt has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Calyxt's dividends in 3 years as they are not expected to pay a notable one for United States of America.
X
Income/ dividend checks
We assess Calyxt's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Calyxt afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Calyxt has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Calyxt's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Jim Blome
COMPENSATION $5,229,684
AGE 56
TENURE AS CEO 1.4 years
CEO Bio

Mr. James A. Blome, also known as Jim, is the Chief Executive Officer of Calyxt since October 1, 2018. He was President and Chief Executive Officer of Bayer CropScience LP till September 2018. He serves as Venture Partner at Builders VC. He serves as vice president at National Wild Turkey Federations Foundation Board. Prior to this, he served as Chief Executive Officer, President and Head of North American Region at Bayer CropScience AG since 2011. Prior to this, he served as Chief Operating Officer and Executive Vice President at Valent U.S.A. Corporation. Prior to this, he served as Executive Vice President of Coastal Division at Agriliance, LLC since December 2006. Prior to this, he served as Vice President of Coastal Sales at Agriliance LLC from July 2003 to December 2006. He has more than 25 years of leadership experience in agriculture to Bayer CropScience. Prior to this, he served as Vice President at Agriliance South from January 2002. Prior to this, he served as President at Agtrol International in Houston since 1998. Prior to this, he served as an Independent Non-Executive Chairman at Inocucor, Inc. since March 3, 2015. He serves as Chairman of Croplife America Inc. He serves as the Chairman of US Farming and Ranching Foundation and Independent Non-Executive Chairman of Concentric Ag Technologies, Inc. He holds a Bachelor's of Science in Agronomy from Iowa State University. He holds a Master's of Business Administration from the University of Northern Iowa and completed additional studies at Philadelphia's Wharton School of Business. He is the 2013 recipient of the Henry A. Wallace Award from Iowa State University for outstanding leadership and service to agriculture.

CEO Compensation
  • Insufficient data for Jim to compare compensation growth.
  • Jim's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Calyxt management team in years:

1
Average Tenure
53
Average Age
  • The average tenure for the Calyxt management team is less than 2 years, this suggests a new team.
Management Team

Jim Blome

TITLE
Chief Executive Officer
COMPENSATION
$5M
AGE
56
TENURE
1.4 yrs

Dan Voytas

TITLE
Founder & Chief Science Officer
COMPENSATION
$283K
AGE
56

Bill Koschak

TITLE
Chief Financial Officer
AGE
50
TENURE
1.2 yrs

Travis Frey

TITLE
Chief Technology Officer
TENURE
0.8 yrs

Debra Frimerman

TITLE
General Counsel
AGE
39
TENURE
1.1 yrs

Trina Lundblad

TITLE
Director of Communications
TENURE
0.8 yrs

Keith Blanks

TITLE
Senior Vice President of Sales & Marketing
TENURE
0.5 yrs

Simon Harnest

TITLE
VP of Corporate Strategy & Finance
Board of Directors Tenure

Average tenure and age of the Calyxt board of directors in years:

1.7
Average Tenure
54
Average Age
  • The average tenure for the Calyxt board of directors is less than 3 years, this suggests a new board.
Board of Directors

André Choulika

TITLE
Chairman of the Board
COMPENSATION
$65K
AGE
54
TENURE
9.6 yrs

Philippe Dumont

TITLE
Independent Director
COMPENSATION
$65K
AGE
68
TENURE
2.7 yrs

Yves Ribeill

TITLE
Independent Director
COMPENSATION
$3M
AGE
59
TENURE
1.7 yrs

Anna Kozicz-Stankiewicz

TITLE
Independent Director
COMPENSATION
$50K
AGE
44
TENURE
2.7 yrs

Jonathan Fassberg

TITLE
Independent Director
COMPENSATION
$534K
AGE
53
TENURE
1.6 yrs

Chris Neugent

TITLE
Independent Director
COMPENSATION
$528K
AGE
58
TENURE
1.5 yrs

Kim Nelson

TITLE
Independent Director
AGE
51
TENURE
1.2 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess Calyxt's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Calyxt has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Calyxt (NASDAQ:CLXT) Is Using Debt In A Risky Way

NasdaqGM:CLXT Historical Debt, July 18th 2019 A Look At Calyxt's Liabilities The latest balance sheet data shows that Calyxt had liabilities of US$4.65m due within a year, and liabilities of US$18.3m falling due after that. … Calyxt boasts net cash, so it's fair to say it does not have a heavy debt load! … If you're interested in investing in businesses that can grow profits without the burden of debt, then check out this free list of growing businesses that have net cash on the balance sheet.

Simply Wall St -

Investors Who Bought Calyxt (NASDAQ:CLXT) Shares A Year Ago Are Now Down 36%

It seems likely some shareholders believe that Calyxt has the funding to invent a new product before too long. … A Different Perspective Given that the market gained 2.8% in the last year, Calyxt shareholders might be miffed that they lost 36%. … However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period.

Simply Wall St -

Those Who Purchased Calyxt (NASDAQ:CLXT) Shares A Year Ago Have A 10% Loss To Show For It

(NASDAQ:CLXT) share price has gained some 80% in the last three months. … Calyxt recorded just US$236,000 in revenue over the last twelve months, which isn't really enough for us to consider it to have a proven product. … But with the share price diving 10% in the last year, it could be that the price was previously too hyped up.

Simply Wall St -

Are Insiders Selling Calyxt, Inc. (NASDAQ:CLXT) Stock?

So shareholders might well want to know whether insiders have been buying or selling shares in Calyxt, Inc. … Calyxt Insider Transactions Over The Last Year … Although we don't gain confidence from insider selling, we note that this large sale was at well above current price of US$13.27

Simply Wall St -

Calyxt Inc's (NASDAQ:CLXT) Path To Profitability

Calyxt, Inc., a consumer-centric food- and agriculture-focused company, develops healthier specialty food ingredients and food crops using gene-editing technology for plants in the United States. … The US$373m market-cap posted a loss in its most recent financial year of -US$26.0m and a latest trailing-twelve-month loss of -US$26.3m leading to an even wider gap between loss and breakeven. … As path to profitability is the topic on CLXT’s investors mind, I’ve decided to gauge market sentiment.

Simply Wall St -

Calyxt Inc (NASDAQ:CLXT) Is Expected To Breakeven

Calyxt, Inc., a consumer-centric food- and agriculture-focused company, develops healthier specialty food ingredients and food crops using gene-editing technology for plants in the United States. … The company’s loss has recently broadened since it announced a -US$25.98m loss in the full financial year, compared to the latest trailing-twelve-month loss of -US$31.70m, moving it further away from breakeven. … In this article, I will touch on the expectations for CLXT’s growth and when analysts expect the company to become profitable

Simply Wall St -

Does Calyxt Inc's (CLXT) Past Performance Indicate A Weaker Future?

I use the ‘latest twelve-month’ data, which either annualizes the most recent 6-month earnings update, or in some cases, the most recent annual report is already the latest available financial data. … This doesn’t seem to paint a better picture, as earnings seem to have steadily been getting more and more negative over time. … I suggest you continue to research Calyxt to get a better picture of the stock by looking at: 1.

Simply Wall St -

Should You Be Concerned About Calyxt Inc's (CLXT) Shareholders?

See our latest analysis for CLXT NasdaqGM:CLXT Ownership Summary Oct 20th 17 Institutional Ownership CLXT's 12.89% institutional ownership seems enough to cause large share price movements in the case of significant share sell-off or acquisitions by institutions, particularly when there is a low level of public shares available on the market to trade. … For CLXT shareholders, the potential of this type of share price volatility shouldn't be as concerning as hedge fund ownership is is not significant,indicating few chances of such sudden price moves. … CLXT's considerably high level of institutional ownership calls for further analysis into its margin of safety.

Simply Wall St -

Company Info

Description

Calyxt, Inc., a consumer-centric food- and agriculture-focused company, develops healthier specialty food ingredients and food crops using gene-editing technology for agriculture in the United States. It engages in the development of high oleic and low linolenic soybean product candidates; high fiber wheat; improved quality alfalfa product candidates; and cold storable and reduced browning potatoes. The company was formerly known as Cellectis Plant Sciences, Inc. and changed its name to Calyxt, Inc. in May 2015. Calyxt, Inc. was founded in 2010 and is headquartered in Roseville, Minnesota. Calyxt, Inc. operates as a subsidiary of Cellectis S.A.

Details
Name: Calyxt, Inc.
CLXT
Exchange: NasdaqGM
Founded: 2010
$123,385,019
32,990,647
Website: http://www.calyxt.com
Address: Calyxt, Inc.
2800 Mount Ridge Road,
Roseville,
Minnesota, 55113,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM CLXT Common Stock Nasdaq Global Market US USD 20. Jul 2017
Number of employees
Current staff
Staff numbers
75
Calyxt employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/03/28 02:41
End of day share price update: 2020/03/27 00:00
Last estimates confirmation: 2020/03/26
Last earnings filing: 2020/03/05
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.